Palmitic acid
|
Basic information |
| Metabolite name | Palmitic acid |
 | HMDB0000220 |
 |
C00249 |
 |
985 |
| Synonyms | Hexadecanoate; |
| No. of studies | 59 |
|
Basic information |
| Metabolite name | Palmitic acid |
| HMDB0000220 |
|
C00249 |
|
985 |
| Synonyms | Hexadecanoate; |
| No. of studies | 59 |
|
Relationship between Palmitic acid and depression (count: 59) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M001 | Type4 | remitted group vs. non-remitted group | Plasma | Human | Up |
| Study M003 | Type1 | day 27 CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M003 | Type1 | day 9 CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M004 | Type2 | CUMS + xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M005 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M009 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M009 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M009 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M009 | Type2 | CUMS + high dose of Xiaoyaosan group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M009 | Type2 | CUMS + middle dose of Xiaoyaosan group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M018 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M018 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M020 | Type1 | CUMS group vs. control group | Heart | Sprague-Dawley rat | Down |
| Study M022 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M028 | Type2 | sertraline group 4-week treatment vs. baseline | Serum | Human | Down |
| Study M041 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M042 | Type3 | fluoxetine group vs. control group | Plasma | Rhesus monkey | Down |
| Study M063 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M063 | Type2 | CUMS + middle dose of the sea buckthorn seed oil group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M063 | Type2 | CUMS + low dose of the sea buckthorn seed oil group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M063 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M064 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M064 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Cecum | Sprague-Dawley rat | Down |
| Study M064 | Type2 | CUMS + fluoxetine group vs. CUMS group | Cecum | Sprague-Dawley rat | Up |
| Study M070 | Type1 | depressed group vs. non-depressed group | Urine | Human | Up |
| Study M071 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6N mouse | Down |
| Study M071 | Type2 | CUMS + imipramine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Up |
| Study M071 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Up |
| Study M075 | Type1 | post stroke depressed group vs. post stroke non-depressed group | Plasma | Human | Up |
| Study M083 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
| Study M102 | Type1 | severe MDD group vs. control group | Urine | Human | Up |
| Study M1024 | Type1 | CUMS group vs. control group | DG region of hippocampus | ICR mouse | Down |
| Study M1024 | Type1 | CUMS group vs. control group | CA1 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type1 | CUMS group vs. control group | CA3 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | DG region of hippocampus | ICR mouse | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | CA1 region of hippocampus | ICR mouse | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | CA3 region of hippocampus | ICR mouse | Up |
| Study M1074 | Type1 | MDD group vs. control group | Serum | Human | Down |
| Study M1075 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M1075 | Type1 | CSDS group vs. control group | Frontal cortex | C57BL/6J mouse | Down |
| Study M1090 | Type1 | CUMS group vs. control group | Plasma | BALb/c mouse | Down |
| Study M1090 | Type3 | hyperbaric oxygen treatment group vs. control group | Plasma | BALb/c mouse | Up |
| Study M1096 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M1096 | Type2 | CUMS + low dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + fluoxetine group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M110 | Type1 | SD group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M113 | Type1 | CUMS group vs. control group | Serum | Wistar rat | Down |
| Study M113 | Type2 | CUMS + exercise group vs. CUMS group | Serum | Wistar rat | Up |
| Study M1143 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M1143 | Type2 | MDD group, after 12-week escitalopram treatment vs. baseline | Plasma | Human | Down |
| Study M129 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M181 | Type3 | venlafaxine group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M181 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M207 | Type1 | depressed group vs. control group | Serum | Kunming mouse | Up |
| Study M463 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M464 | Type1 | drug-treatment MDD group vs. control group | Plasma | Human | Down |
| Study M464 | Type1 | drug-naive MDD group vs. control group | Plasma | Human | Down |
| Study M472 | Type3 | (2R,6R)-HNK group vs. control group | PC12 cell | Rat | Down |
| Study M510 | Type1 | LQS group vs. control group | Urine | Human | Up |
| Study M536 | Type1 | naturally-occurring depression group vs. control group | Cerebrospinal fluid | Cynomolgus monkey | Up |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M568 | Type1 | high-fat diet group vs. control group | Hypothalamus | C57BL/6J mouse | Up |
| Study M610 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M610 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M611 | Type1 | LPS group vs. control group | Liver | Sprague-Dawley rat | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Heart | Sprague-Dawley rat | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Kidney | Sprague-Dawley rat | Unknown |
| Study M661 | Type1 | PSD group vs. stroke group | Plasma | Human | Down |
| Study M668 | Type1 | PSD group vs. stroke group | Urine | Human | Down |
| Study M669 | Type1 | corticosterone group vs. control group | Liver | C57BL/6J mouse | Up |
| Study M681 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M681 | Type2 | CUMS + Chaihu Shu Gan San group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M685 | Type1 | SDS group vs. control group | Nucleus accumbens | C57BL/6J mouse | Up |
| Study M715 | Type1 | MDD group vs. control group | Faece | Human | Down |
| Study M757 | Type1 | PSD group vs. stroke group | Urine | Human | Up |
| Study M769 | Type1 | CSDS group vs. control group | Amygdala | Sprague-Dawley rat | Up |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Up |
| Study M826 | Type1 | CVS group vs. control group | Gut | Wistar rat | Up |
| Study M826 | Type1 | CVS group vs. control group | Ileum | Wistar rat | Up |
| Study M826 | Type1 | CVS group vs. control group | Colorectum | Wistar rat | Up |
| Study M826 | Type2 | CVS + antibiotic group vs. CVS group | Gut | Wistar rat | Down |
| Study M838 | Type1 | MS + stranger group vs. control group | Faece | Wistar rat | Down |
| Study M838 | Type1 | MS group vs. control group | Faece | Wistar rat | Down |
| Study M838 | Type2 | MS + Lactobacillus paracasei group vs. MS group | Faece | Wistar rat | Up |
| Study M838 | Type2 | MS + stranger + Lactobacillus paracasei group vs. MS + stranger group | Faece | Wistar rat | Up |
| Study M867 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M869 | Type1 | CUMS group vs. control group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Down |
| Study M869 | Type2 | CUMS + middle dose of Chaigui granules group vs. CUMS group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Up |
| Study M870 | Type1 | CRS group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M870 | Type2 | CRS + middle dose of Jia Wei Xiao Yao San group vs. CRS group | Brain | C57BL/6 mouse | Up |
| Study M894 | Type2 | electromagnetic field exposure + heat acclimation group vs. electromagnetic field exposure group | Serum | C57BL/6J mouse | Down |
| Study M907 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M911 | Type1 | CUS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M935 | Type4 | chronic social isolation + tianeptine group vs. chronic social isolation + tianeptine resilient group | Hippocampus | Wistar rat | Up |
| Study M953 | Type2 | CRS + Shugan Granule group vs. CRS group | Faece | Sprague-Dawley rat | Up |
| Study M981 | Type1 | Abeta oligomer group vs. control group | Serum | ICR mouse | Down |
| Study M981 | Type2 | Abeta oligomer + involuntary and voluntary running + acousto-optic stimulation group vs. Abeta oligomer group | Serum | ICR mouse | Down |